Source link : https://www.newshealth.biz/health-news/asco-advises-on-cdk4-6-inhibitors-for-breast-cancer/
TOPLINE: A rapid recommendation update from the American Society of Clinical Oncology (ASCO) offers guidance on use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, abemaciclib and ribociclib, for the adjuvant treatment of stages II and III breast cancer. METHODOLOGY: The guideline update was needed to incorporate new high-quality evidence for the adjuvant use of […]
Author : News Health
Publish date : 2024-05-30 08:38:33
Copyright for syndicated content belongs to the linked Source.
in Health